Cargando…
Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis
Sporadic inclusion body myositis (s-IBM) is characterized histologically by the association of concomitant inflammatory and degenerative processes. We evaluated the sensitivity and specificity of different markers of the degenerative process in order to refine the histological diagnosis. We performe...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pacini Editore SpA
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235833/ https://www.ncbi.nlm.nih.gov/pubmed/22106712 |
_version_ | 1782218643369623552 |
---|---|
author | Dubourg, O. Wanschitz, J. Maisonobe, T. Béhin, A. Allenbach, Y. Herson, S. Benveniste, O |
author_facet | Dubourg, O. Wanschitz, J. Maisonobe, T. Béhin, A. Allenbach, Y. Herson, S. Benveniste, O |
author_sort | Dubourg, O. |
collection | PubMed |
description | Sporadic inclusion body myositis (s-IBM) is characterized histologically by the association of concomitant inflammatory and degenerative processes. We evaluated the sensitivity and specificity of different markers of the degenerative process in order to refine the histological diagnosis. We performed an immunohistochemical study with antibodies directed against ubiquitin, amyloid-β precursor protein (AβPP), amyloid-β (Aβ), SMI-31, SMI-310, Tar-DNA binding protein-43 (TDP-43) and p62 on s-IBM and control muscle biopsies. Based on conventional stains 36 patients with characteristic clinical features of s-IBM were subclassified as presumed definite s-IBM (d s-IBM, n = 17) or possible s-IBM (p s-IBM, n = 19) according to the presence or absence of vacuolated muscle fibers. Immunohistochemically, TDP-43 and p62 were the most sensitive markers, accumulating in all d s-IBM and in 31% and 37%, respectively, of the p s-IBM cases and thus enabling reclassification of these cases as d s-IBM. We recommend using TDP-43 and p62 antibodies in the histological diagnosis workup of s-IBM. The specificity of these markers has to be further validated in prospective series. |
format | Online Article Text |
id | pubmed-3235833 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Pacini Editore SpA |
record_format | MEDLINE/PubMed |
spelling | pubmed-32358332012-01-20 Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis Dubourg, O. Wanschitz, J. Maisonobe, T. Béhin, A. Allenbach, Y. Herson, S. Benveniste, O Acta Myol Articles in Tribute of V. Askanas and K. Engel Sporadic inclusion body myositis (s-IBM) is characterized histologically by the association of concomitant inflammatory and degenerative processes. We evaluated the sensitivity and specificity of different markers of the degenerative process in order to refine the histological diagnosis. We performed an immunohistochemical study with antibodies directed against ubiquitin, amyloid-β precursor protein (AβPP), amyloid-β (Aβ), SMI-31, SMI-310, Tar-DNA binding protein-43 (TDP-43) and p62 on s-IBM and control muscle biopsies. Based on conventional stains 36 patients with characteristic clinical features of s-IBM were subclassified as presumed definite s-IBM (d s-IBM, n = 17) or possible s-IBM (p s-IBM, n = 19) according to the presence or absence of vacuolated muscle fibers. Immunohistochemically, TDP-43 and p62 were the most sensitive markers, accumulating in all d s-IBM and in 31% and 37%, respectively, of the p s-IBM cases and thus enabling reclassification of these cases as d s-IBM. We recommend using TDP-43 and p62 antibodies in the histological diagnosis workup of s-IBM. The specificity of these markers has to be further validated in prospective series. Pacini Editore SpA 2011-10 /pmc/articles/PMC3235833/ /pubmed/22106712 Text en The journal and the individual contributions contained in it are protected by the copyright of Gaetano Conte Academy, Naples, Italy http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License, which permits for noncommercial use, distribution, and reproduction in any digital medium, provided the original work is properly cited and is not altered in any way. For details, please refer to http://creativecommons.org/licenses/by-nc-nd/3.0/ |
spellingShingle | Articles in Tribute of V. Askanas and K. Engel Dubourg, O. Wanschitz, J. Maisonobe, T. Béhin, A. Allenbach, Y. Herson, S. Benveniste, O Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis |
title | Diagnostic value of markers of muscle
degeneration in sporadic inclusion
body myositis |
title_full | Diagnostic value of markers of muscle
degeneration in sporadic inclusion
body myositis |
title_fullStr | Diagnostic value of markers of muscle
degeneration in sporadic inclusion
body myositis |
title_full_unstemmed | Diagnostic value of markers of muscle
degeneration in sporadic inclusion
body myositis |
title_short | Diagnostic value of markers of muscle
degeneration in sporadic inclusion
body myositis |
title_sort | diagnostic value of markers of muscle
degeneration in sporadic inclusion
body myositis |
topic | Articles in Tribute of V. Askanas and K. Engel |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235833/ https://www.ncbi.nlm.nih.gov/pubmed/22106712 |
work_keys_str_mv | AT dubourgo diagnosticvalueofmarkersofmuscledegenerationinsporadicinclusionbodymyositis AT wanschitzj diagnosticvalueofmarkersofmuscledegenerationinsporadicinclusionbodymyositis AT maisonobet diagnosticvalueofmarkersofmuscledegenerationinsporadicinclusionbodymyositis AT behina diagnosticvalueofmarkersofmuscledegenerationinsporadicinclusionbodymyositis AT allenbachy diagnosticvalueofmarkersofmuscledegenerationinsporadicinclusionbodymyositis AT hersons diagnosticvalueofmarkersofmuscledegenerationinsporadicinclusionbodymyositis AT benvenisteo diagnosticvalueofmarkersofmuscledegenerationinsporadicinclusionbodymyositis |